OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Richter on the Importance of Optimizing Available Therapies in Multiple Myeloma

September 2nd 2020

Joshua Richter, MD, discusses the importance of optimizing available therapies in multiple myeloma.

Dr. Grothey on Left- Versus Right-Sided Tumors in CRC

September 2nd 2020

Axel Grothey, MD, discusses left- versus right-sided tumors in colorectal cancer.

Dr. Rizvi on Utilizing Molecular Characteristics to Inform Treatment Decisions in NSCLC

September 2nd 2020

Naiyer A. Rizvi, MD, discusses treatment approaches in non–small cell lung cancer.

Dr. Moore on Anticipated Impact of the MIRASOL Trial in Platinum-Resistant Ovarian Cancer

September 2nd 2020

Kathleen Moore, MD, discusses the anticipated impact of the phase 3 MIRASOL trial with mirvetuximab soravtansine in patients with platinum-resistant, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer with a high folate receptor alpha expression.

Dr. Nguyen on the Role of Radiation Therapy in High-Risk Prostate Cancer

September 2nd 2020

Paul L. Nguyen, MD, discusses the role of radiation therapy in high-risk prostate cancer.

Dr. Hill on the Challenges of Managing Heavily Pretreated DLBCL

September 2nd 2020

Brian T. Hill, MD, PhD, discusses the challenges of managing heavily pretreated patients with diffuse large B-cell lymphoma.

Dr. Tripathy on the Evolving Treatment Landscape of HER2+ Breast Cancer

September 2nd 2020

Debu Tripathy, MD, discusses the evolving treatment landscape of HER2-positive breast cancer.

Dr. VanderWalde on Utility of Radiation Therapy in Rectal Cancer

September 1st 2020

Noam VanderWalde, MD, MS, discusses radiation therapy in early-stage versus later-stage rectal cancer.

Dr. Richard on the Evolving Armamentarium in Multiple Myeloma

September 1st 2020

Shambavi Richard, MD, highlights the rapidly evolving armamentarium in multiple myeloma.

Dr. Halfdanarson on the KEYNOTE-177 Trial in MSI-H/dMMR mCRC

September 1st 2020

Thorvardur (Thor) Halfdanarson, MD, discusses the KEYNOTE-177 trial in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer.

Dr. Maddocks on Emerging Therapies in Follicular Lymphoma

September 1st 2020

Kami J. Maddocks, MD, discusses emerging therapies in follicular lymphoma.

Dr. Soliman the Utility of ADCs in Breast Cancer

September 1st 2020

Hatem Soliman, MD, discusses the utility of antibody-drug conjugates in breast cancer.

Dr. Han on the Importance of Risk Stratification in HER2+ Breast Cancer

September 1st 2020

Heather S. Han, MD, discusses the importance of risk stratification in HER2-positive breast cancer.

Dr. Alkharabsheh on the Goals of Treatment in MPNs

September 1st 2020

Omar Alkharabsheh, MD, discusses the current goals of treatment in myeloproliferative neoplasms.

Dr. Roland on Findings From a Phase 2 Study With Neoadjuvant Checkpoint Blockade in Sarcoma

September 1st 2020

Christina L. Roland, MD, MS, FACS, discusses the results from a phase 2 study evaluating neoadjuvant checkpoint blockade study in patients with undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.

Dr. Pennell on the Evolution of Targeting HER2 in Lung Cancer

September 1st 2020

Nathan A. Pennell, MD, PhD, discusses the evolution of targeting HER2 in lung cancer.

Dr. DiNardo on the FDA Approval of Oral Azacitidine in AML

September 1st 2020

Courtney DiNardo, MD, MSCE, discusses the FDA approval of oral azacitidine (CC-486) in acute myeloid leukemia (AML).

Dr. Flinn on the Design of a Phase 2 Trial of Zanubrutinib in CLL/SLL

August 31st 2020

Ian W. Flinn, MD, PhD, discusses the design of a phase 2 trial evaluating zanubrutinib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Dr. Greenlee on Mitigating the Risk of Cardiovascular Disease in Breast Cancer

August 31st 2020

Heather Greenlee, ND, PhD, MPH, provides strategies to mitigate the increased risk of cardiovascular disease in women with breast cancer.

Dr. Lai on the Potential Benefits of Venetoclax in AML

August 31st 2020

Catherine Lai, MD, MPH, discusses the potential benefits of venetoclax in acute myeloid leukemia.